# Rajvir Dahiya

Rajvir Dahiya (born May 30, 1956) is an American Indian medical oncology scientist with expertise in urology oncology diagnosis, prognosis and risk assessment through genetic and epigenetic technology. Dahiya retired in 2021 as a Professor Emeritus and Director of Urology Oncology Research Center at the Veterans Affairs Medical Center and the University of California San Francisco School of Medicine (UCSF) after 34 years of service.
After retirement, Dahiya founded Geneverify Inc. in 2021, a company registered in California, USA. The company is dedicated to research and development in precision oncology, particularly in the creation of in vitro diagnostic tests for cancer screening, early diagnosis, prognosis, and treatment follow-up. Geneverify is also working on developing novel medical technologies that target oncogenes, aiming to provide the most effective and highly specific treatments for various cancers, potentially saving the lives of millions of cancer patients.

## Early life and family

Dahiya was born in Bidhlan, Sonipat, Haryana, India. His parents were farmers. He finished his PhD in 1983 in the field of Experimental Medicine from Post Graduate Institute of Medical Education and Research Chandigarh, India. After completing his PhD, Dahiya joined the University of Chicago Pritzker School of Medicine and did his post doctoral fellowship in medical oncology and molecular biology. After completing his fellowship, Dahiya joined UCSF School of Medicine and San Francisco Veterans Affairs Medical Center (VAMC) in 1987. Dahiya received his M.D. from the Kagoshima University Faculty of Medicine, Kagoshima, Japan and D.Sc. from the Osaka University Graduate School of Medicine, Osaka, Japan. He became director of Oncology Urology Oncology Research Center at the UCSF/VAMC in 1991. After 34 years of service at the UCSF, he retired as a Professor Emeritus and Director of Urology Research Center. Also retired as a Senior Research Career Scientist from the Department of Veterans Affairs, Washington DC.

## Positions and publications

Dahiya was a scientific reviewer and chairman (1996-2021) for the medical research programs in prostate, ovarian and breast cancer at the United States Army Department of Defense’s (DOD). He was also a member and chairman (1992-2021) of various scientific committees for National Institutes of Health (NIH), including the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dahiya is a medical research advisor and scientific reviewer for several international programs and institutions.
Dahiya has published more than 550 original research manuscripts. Dahiya’s world ranking in medicine is 4759 and USA ranking is 2644 with more than 35,500 research citations and D-index of 107 in 2024. He has written books and holds multiple patents in oncology. Based on the NIH and VA data base NIH Reporter and Grantome, Dahiya's research programs were supported (99 times awarded) by the NIH and VA. Dahiya was a scientific adviser to the President of India Dr. A.P.J. Abul Kalam (Avul Pakir Jainulabdeen Abdul Kalam, 11th President of India from 2002-2007).
Dr. Rajvir Dahiya and Dr. Dharampal Singh Chauhan are discussing with the President of India about the transfer of medical technologies from the USA to India in the field of cancer diagnosis, prognosis and treatment that would save the lives of millions of cancer patients. Dahiya is an Associate Editor of Cancer Research, is an Associate Editor of Clinical Cancer Research, an Academic Editor of “PLoS ONE, and a senior academic editor of American Journal of Cancer Research.
Dahiya (President) and Chauhan (Secretary) of "Society of American Asian Scientists in Cancer Research" are leading this society that has more than 5,000 cancer scientists in the USA.

## Retractions

In 2022 it was reported that a joint investigation by the University of California San Francisco and the San Francisco Veterans Affairs Medical Center revealed examples of fabrication or falsification in some of Dahiya's published work. As of 2022 Dahiya has had four of his research publications retracted, one paper has received an expression of concern, and one paper has been corrected. It appears that this issue may have resulted from a UCSF data preservation policy.